196 related articles for article (PubMed ID: 30983083)
1. Hepatitis C virus infection and non-hepatocellular malignancies in the DAA era: A systematic review and meta-analysis.
Masarone M; Persico M
Liver Int; 2019 Jul; 39(7):1292-1306. PubMed ID: 30983083
[TBL] [Abstract][Full Text] [Related]
2. The anti-lymphoma activity of antiviral therapy in HCV-associated B-cell non-Hodgkin lymphomas: a meta-analysis.
Peveling-Oberhag J; Arcaini L; Bankov K; Zeuzem S; Herrmann E
J Viral Hepat; 2016 Jul; 23(7):536-44. PubMed ID: 26924533
[TBL] [Abstract][Full Text] [Related]
3. Expert opinion on managing chronic HCV in patients with non-Hodgkin lymphoma and other extrahepatic malignancies.
Ferri C; Feld JJ; Bondin M; Cacoub P
Antivir Ther; 2018; 23(Suppl 2):23-33. PubMed ID: 30451149
[TBL] [Abstract][Full Text] [Related]
4. miRNA-26b downregulation in peripheral blood mononuclear cells of patients with hepatitis C associated lymphomas is restored by successful interferon-free antiviral therapy.
Peveling-Oberhag J; Bankov K; Dultz G; Ballo O; Lohmeyer J; Brunnberg U; Marcu V; Walter D; Zeuzem S; Hansmann ML; Welzel TM; Vermehren J
Antivir Ther; 2019; 24(6):437-442. PubMed ID: 31180334
[TBL] [Abstract][Full Text] [Related]
5. Hepatitis B virus reactivation during direct-acting antiviral therapy for hepatitis C: a systematic review and meta-analysis.
Mücke MM; Backus LI; Mücke VT; Coppola N; Preda CM; Yeh ML; Tang LSY; Belperio PS; Wilson EM; Yu ML; Zeuzem S; Herrmann E; Vermehren J
Lancet Gastroenterol Hepatol; 2018 Mar; 3(3):172-180. PubMed ID: 29371017
[TBL] [Abstract][Full Text] [Related]
6. Hepatocellular carcinoma decreases the chance of successful hepatitis C virus therapy with direct-acting antivirals.
Prenner SB; VanWagner LB; Flamm SL; Salem R; Lewandowski RJ; Kulik L
J Hepatol; 2017 Jun; 66(6):1173-1181. PubMed ID: 28161470
[TBL] [Abstract][Full Text] [Related]
7. Extrahepatic Malignancy Among Patients With Chronic Hepatitis C After Antiviral Therapy: A Real-World Nationwide Study on Taiwanese Chronic Hepatitis C Cohort (T-COACH).
Huang CF; Lai HC; Chen CY; Tseng KC; Kuo HT; Hung CH; Wang JH; Chen JJ; Lee PL; Chien RN; Yang CC; Lo GH; Tai CM; Lin CW; Kao JH; Liu CJ; Liu CH; Yan SL; Bair MJ; Lin CY; Su WW; Chu CH; Chen CJ; Tung SY; Lo CC; Cheng PN; Chiu YC; Wang CC; Cheng JS; Tsai WL; Lin HC; Huang YH; Yeh ML; Huang JF; Dai CY; Chuang WL; Tsai PC; Peng CY; Yu ML
Am J Gastroenterol; 2020 Aug; 115(8):1226-1235. PubMed ID: 32221162
[TBL] [Abstract][Full Text] [Related]
8. Impact of antiviral therapy on hepatocellular carcinoma and mortality in patients with chronic hepatitis C: systematic review and meta-analysis.
Bang CS; Song IH
BMC Gastroenterol; 2017 Apr; 17(1):46. PubMed ID: 28376711
[TBL] [Abstract][Full Text] [Related]
9. Direct-acting antiviral treatment of chronic HCV-infected patients on opioid substitution therapy: Still a concern in clinical practice?
Christensen S; Buggisch P; Mauss S; Böker KHW; Schott E; Klinker H; Zimmermann T; Weber B; Reimer J; Serfert Y; Wedemeyer H
Addiction; 2018 May; 113(5):868-882. PubMed ID: 29359361
[TBL] [Abstract][Full Text] [Related]
10. Hepatitis C virus eradication by direct-acting antiviral agents improves carotid atherosclerosis in patients with severe liver fibrosis.
Petta S; Adinolfi LE; Fracanzani AL; Rini F; Caldarella R; Calvaruso V; Cammà C; Ciaccio M; Di Marco V; Grimaudo S; Licata A; Marrone A; Nevola R; Pipitone RM; Pinto A; Rinaldi L; Torres D; Tuttolomondo A; Valenti L; Fargion S; Craxì A
J Hepatol; 2018 Jul; 69(1):18-24. PubMed ID: 29505844
[TBL] [Abstract][Full Text] [Related]
11. Hepatitis C-associated B-cell non-Hodgkin lymphomas. Epidemiology, molecular signature and clinical management.
Peveling-Oberhag J; Arcaini L; Hansmann ML; Zeuzem S
J Hepatol; 2013 Jul; 59(1):169-77. PubMed ID: 23542089
[TBL] [Abstract][Full Text] [Related]
12. Safety and Effectiveness of Direct-Acting Antiviral Agents for Treatment of Patients With Chronic Hepatitis C Virus Infection and Cirrhosis.
Maan R; van Tilborg M; Deterding K; Ramji A; van der Meer AJ; Wong F; Fung S; Sherman M; Manns MP; Cornberg M; Hansen BE; Wedemeyer H; Janssen HL; de Knegt RJ; Feld JJ
Clin Gastroenterol Hepatol; 2016 Dec; 14(12):1821-1830.e6. PubMed ID: 27404965
[TBL] [Abstract][Full Text] [Related]
13. Viral eradication reduces all-cause mortality in patients with chronic hepatitis C virus infection: a propensity score analysis.
Tada T; Kumada T; Toyoda H; Kiriyama S; Tanikawa M; Hisanaga Y; Kanamori A; Kitabatake S; Yama T; Tanaka J
Liver Int; 2016 Jun; 36(6):817-26. PubMed ID: 26787002
[TBL] [Abstract][Full Text] [Related]
14. Interferon-free therapies for patients with chronic hepatitis C genotype 3 infection: A systematic review.
Gimeno-Ballester V; Buti M; San Miguel R; Riveiro M; Esteban R
J Viral Hepat; 2017 Nov; 24(11):904-916. PubMed ID: 27925386
[TBL] [Abstract][Full Text] [Related]
15. From hepatitis C virus infection to B-cell lymphoma.
Couronné L; Bachy E; Roulland S; Nadel B; Davi F; Armand M; Canioni D; Michot JM; Visco C; Arcaini L; Besson C; Hermine O
Ann Oncol; 2018 Jan; 29(1):92-100. PubMed ID: 29045541
[TBL] [Abstract][Full Text] [Related]
16. Antiviral treatment for hepatitis C is associated with a reduced risk of atherosclerotic cardiovascular outcomes: A systematic review and meta-analysis.
Su X; Zhao X; Deng JL; Li SN; Du X; Dong JZ; Ma CS
J Viral Hepat; 2021 Apr; 28(4):664-671. PubMed ID: 33452699
[TBL] [Abstract][Full Text] [Related]
17. Sustained virologic response by direct antiviral agents reduces the incidence of hepatocellular carcinoma in patients with HCV infection.
Kobayashi M; Suzuki F; Fujiyama S; Kawamura Y; Sezaki H; Hosaka T; Akuta N; Suzuki Y; Saitoh S; Arase Y; Ikeda K; Kumada H
J Med Virol; 2017 Mar; 89(3):476-483. PubMed ID: 27531586
[TBL] [Abstract][Full Text] [Related]
18. The impact of antiviral therapy on the course of chronic HCV infection. A systematic review.
Almasio PL; Venezia G; Craxì A
Panminerva Med; 2003 Sep; 45(3):175-82. PubMed ID: 14618115
[TBL] [Abstract][Full Text] [Related]
19. The impact of interferon-free direct-acting antivirals on clinical outcome after curative treatment for hepatitis C virus-associated hepatocellular carcinoma: Comparison with interferon-based therapy.
Nagaoki Y; Imamura M; Nishida Y; Daijo K; Teraoka Y; Honda F; Nakamura Y; Morio K; Fujino H; Nakahara T; Kawaoka T; Tsuge M; Hiramatsu A; Kawakami Y; Miki D; Hiyama Y; Ochi H; Chayama K; Aikata H
J Med Virol; 2019 Apr; 91(4):650-658. PubMed ID: 30381831
[TBL] [Abstract][Full Text] [Related]
20. Concomitant therapy with direct-acting antivirals and chemoimmunotherapy in HCV-associated diffuse large B-cell lymphoma.
Occhipinti V; Farina L; Viganò M; Capecchi M; Labanca S; Fanetti I; Corradini P; Rumi M
Dig Liver Dis; 2019 May; 51(5):719-723. PubMed ID: 30502232
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
